Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964490 | 0.90 | HTR2C (0.33) | HTR2CSLC6A4ALOX5AP | |
| SCHEMBL959862 | 0.82 | HTR2C (0.34) | HTR2CSLC6A4 | |
| SCHEMBL960988 | 0.81 | HTR2C (0.34) | HTR2CSLC6A4 | |
| SCHEMBL962329 | 0.80 | HTR2C (0.33) | HTR2CSLC6A4 | |
| SCHEMBL113359 | 0.79 | ALOX5AP (0.34) | ALOX5AP | |
| SCHEMBL1006155 | 0.79 | HTR2C (0.33) | HTR2CSLC6A4 | |
| SCHEMBL1006156 | 0.79 | HTR2C (0.33) | HTR2CSLC6A4 | |
| SCHEMBL959896 | 0.77 | ALOX5AP (0.36) | ALOX5AP | |
| SCHEMBL167647 | 0.76 | HTR2C (0.35) | HTR2CSLC6A4 | |
| SCHEMBL113587 | 0.76 | ALOX5AP (0.36) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2264026-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | NPY4R, NPY1R, NPY2R | HTR2C 254/4885SLC6A4 478/4885ALOX5AP 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.